Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study.

BMC cancer - 16 Jul 2021

Tang Xin, Qian Wen-Lei, Yan Wei-Feng, Pang Tong, Gong You-Ling, Yang Zhi-Gang

Abstract excerpt

BACKGROUND: Tumor mutation burden (TMB) is an emerging prognostic biomarker of immunotherapy for bladder cancer (BLCA). We aim at investigating radiomic features' value in predicting the TMB status of BLCA patients. METHODS: Totally, 75 patients with BLCA were enrolled. Radiomic features extracted from the volume of interest of preoperative pelvic contrast-enhanced computed tomography (CECT) were obtained for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Feasibility Studies
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Tumor Burden

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34271855
DOI: 10.1186/s12885-021-08569-y
PMCID: PMC8285848

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study.PMID 34271855Read ↗

CT-based radiomics nomogram analysis for assessing BRCA mutation status in patients with high-grade serous ovarian cancer.Semantic proximity Read ↗

Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.Semantic proximity Read ↗

CT Radiomics-Clinical Model for Noninvasive Prediction of Tumor Mutation Burden and Survival in Locally Advanced Head and Neck Squamous Cell CarcinomaSemantic proximity Read ↗

5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancerSemantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypesSemantic proximity Read ↗

Development of an m6A subtype classifier to guide precision therapy for patients with bladder cancerSemantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.Semantic proximity Read ↗

Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.Semantic proximity Read ↗

Advances in risk stratification of bladder cancer to guide personalized medicineSemantic proximity Read ↗

Hypoxia score for predicting prognosis and tumor response to immunotherapy in bladder urothelial carcinomaSemantic proximity Read ↗

MRI T2WI-based radiomics combined with KRAS gene mutation constructed models for predicting liver metastasis in rectal cancer.Semantic proximity Read ↗

Prediction of EGFR mutation status in non-small cell lung cancer based on multiparametric MRI radiomics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.